EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece
Abstract
Authors
N Yfantopoulos I Gountas C Athanasopoulos A Haiderali M Huang A Skroumpelos A Karokis